Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

Abstract: The present invention relates to compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with coronavirus infections. The compositions comprise therapeutically effective amounts of a TLR2 agonist. Certain embodiments specify that the TLR2 agonist is a pegylated, palmitoylated-cysteine compound of Formula (I), (VI), (VII) or (VIII).

Abstract: Methods, compounds, compositions and kits for the treatment and/or prevention of cancer are provided. In particular, methods for the treatment of cancer comprising the administration of a TLR2 agonist, such as a conjugate of dipalmitoyl-S-glyceryl-cysteine (Pam2Cys) and polyethylene glycol (PEG), more particularly a Pam2Cys-Ser-PEG compound, and an immunostimulant such as an anti-PD-1, anti-PDL-1, anti-PL-1, or anti-CTLA-4 immunotherapeutic, are provided.

Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

Abstract: Methods, compounds, compositions, and kits for the treatment of cancer, comprising TLR2 agonists, particularly di-palmitoyl-S-glyceryl-cysteine (Pam2Cys) derivatives and conjugates, are provided. In one aspect, methods of treating, preventing or minimizing the progression of cancer comprising the administration of a compound comprising a Pam2Cys moiety and a polyethylene glycol (PEG) are provided.

Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

Abstract: The present invention relates to methods of treating or preventing respiratory conditions. In particular, the methods relate to treatment of respiratory conditions associated with a virus, such as influenza. In particular, the present invention provides a method of treating or preventing a respiratory condition associated with an infectious agent in an individual, the method comprising administering a compound comprising a TLR2 agonist to the upper respiratory tract of the individual, thereby treating or preventing a respiratory condition associated with an infectious agent in the individual. The compound is not administered to the lower respiratory tract or to both the upper and lower respiratory tract (i.e. administered to the total respiratory tract).

Abstract: The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and/or treatment of rhinovirus infection and the prevention and/or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier.

Abstract: Disclosed herein are methods and compositions for modulating HIV infection by regulating expression of one or more receptors.

Abstract: We disclose a polypeptide capable of binding to a nucleic acid comprising a receptor nucleotide sequence.

Abstract: We disclose a polypeptide capable of binding to a nucleic acid comprising a viral nucleotide sequence. Preferably, the viral nucleotide sequence comprises a viral promoter sequence, for example, an HIV promoter or a herpesvirus promoter sequence.